Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors

Finzel S, Kraus S, Schmidt S, Hueber A, Rech J, Engelke K, Englbrecht M, Schett G (2013)

Publication Type: Journal article

Publication year: 2013

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 72

Pages Range: 1176-1181

Journal Issue: 7

DOI: 10.1136/annrheumdis-2012-201580

Abstract

Objectives: To investigate whether methotrexate or tumour necrosis factor inhibitors (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with PsA were examined for the presence of osteophytes and erosions at the metacarpophalangeal joints by high-resolution micro-CT imaging. The size of each individual lesion was quantified at baseline and 1-year follow-up in PsA patients treated with TNFi (N=28) or methotrexate (N=13). Groups were comparable for age, sex, disease duration and activity and baseline burden of osteophytes. Results: In total, 415 osteophytes (TNFi N=284, methotrexate N=131) were detected. Osteophyte size increased significantly from baseline to follow-up in the TNFi group (mean±SEM change +0.23±0.02 mm; p<0.0001) and the methotrexate group (+0.27±0.03 mm, p<0.0001). In both treatment groups, the majority of osteophytes showed progression (TNFi 54.3%, methotrexate 61.1%), whereas regression of lesions was rare (less than 10%). In contrast to osteophytes, clinical disease activity decreased in both groups of PsA patients and erosions showed an arrest of progression in both groups. Conclusions: Osteophytes progress in PsA patients treated with either methotrexate or TNFi. These data provide the first evidence that pathological bone formation in the appendicular skeleton of patients with PsA is not affected by current antirheumatic treatment strategies.

Authors with CRIS profile

Stephanie Finzel Lehrstuhl für Innere Medizin III Sebastian Kraus Lehrstuhl für Innere Medizin III Sarah Schmidt Medizinische Fakultät Axel Hueber Department of Medicine 3 – Rheumatology and Immunology Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology Klaus Engelke Lehrstuhl für Medizinische Physik und Mikrogewebetechnik Matthias Englbrecht Lehrstuhl für Innere Medizin III Georg Schett Lehrstuhl für Innere Medizin III

How to cite

APA:

Finzel, S., Kraus, S., Schmidt, S., Hueber, A., Rech, J., Engelke, K.,... Schett, G. (2013). Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases, 72(7), 1176-1181. https://doi.org/10.1136/annrheumdis-2012-201580

MLA:

Finzel, Stephanie, et al. "Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors." Annals of the Rheumatic Diseases 72.7 (2013): 1176-1181.

BibTeX: Download